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ABSTRACT
Randomized control trials (RCT’s) are the gold standard in evaluating and efficiently translating research data into clinical 
practice. The CONSORT statement was conceptualized in order to help ascertain standardization and reproducibility of 
RCT’s. The articles publishing the CONSORT 2010 statement along with their bibliographies were identified and thoroughly 
reviewed. The CONSORT statement is made up of a 25-item checklist that provides the author with a solid backbone around 
which to construct and present an RCT. It sets standards on the trial’s design, analysis, and interpretation of the results.
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Introduction
Different epidemiological study designs are available, one of 
which is the randomized control trial (RCT). RCTs are the gold 
standard in evaluating and efficiently translating research data 
into clinical practice. In fact, this type of study provides the 
fundamentals of evidence‑based medicine and is the most 
reliable research design out of all of the epidemiological 
studies available.[1] Therefore reporting of these invaluable 
interventions require high‑quality reporting techniques, which 
allow transparency while enabling the readers to critically 
appraise the trial findings. In order to avoid systematic 
reporting errors while ascertaining the high‑quality reporting 
standards of RCTs, the CONSORT statement was coined in 
1996.[2] The CONSORT was revised over the years to provide 
clearer explanations and elaborations of the CONSORT 
principles. The last version was established in 2010 (available 
at www.consort‑statement.org), on which this article will be 
based.[2] In fact, the original articles publishing the CONSORT 
2010 statement together with their bibliographies were 
identified and thoroughly reviewed.
The CONSORT Statement
The CONSORT stands for “Consolidated Standards of 
Reporting Trails” and was developed to aid authors to present 
the RCTs in a clean, transparent and complete manner, and 
not to act as a quality assessment tool. The CONSORT is 
composed of a 25‑item checklist, which focuses on the 
reporting of the trial design, analysis, and interpretation, as 
seen in Table 1.[2–4] A CONSORT flowchart is also available, 
which displays the progress of all participants through the 
trail, as seen in Figure 1.[4]
The CONSORT checklist
A brief description of each checklist item is provided below.[2,3]
Item 1: Title and abstract
The manuscript title should include the words “randomized 
trial” in order to ensure correct indexing of the manuscript 
in electronic databases. Indexing of the published manuscript 
is of utmost importance to ensure identification of the 
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Table 1: The CONSORT 2010 checklist
CONSORT 2010 checklist
Section/topic Item number Checklist item
Title and abstract 1a Identification as a randomized trial in the title
1b Structured summary of trial design, methods, results, and conclusions
Introduction
Background and objectives 2a Scientific background and explanation of the rationale
2b Specific objectives or hypotheses
Methods
Trial design 3a Description of trial design (such as parallel, factorial) including allocation ratio
3b Important changes to methods after trial commencement (such as eligibility criteria), 
with reasons
Participants 4a Eligibility criteria for participants
4b Settings and locations where the data were collected
Interventions 5 The interventions for each group with sufficient details to allow replication, including 
how and when they were actually administered
Outcomes 6a Completely defined pre-specified primary and secondary outcome measures, 
including how and when they were assessed
6b Any changes to trial outcomes after the trial commenced, with reasons
Sample size 7a How sample size was determined?
7b When applicable, explanation of any interim analyses and stopping guidelines
Randomization
Sequence generation 8a The method used to generate the random allocation sequence
8b Type of randomization; details of any restriction (such as blocking and block size)
Allocation concealment mechanism 9 The mechanism used to implement the random allocation sequence (such as 
sequentially numbered containers), describing any steps taken to conceal the 
sequence until interventions were assigned
Implementation 10 Who generated the random allocation sequence, who enrolled participants, and who 
assigned participants to interventions
Blinding 11a If done, who was blinded after assignment to interventions (e.g., participants, care 
providers, those assessing outcomes) and how
11b If relevant, description of the similarity of interventions
Statistical methods 12a Statistical methods used to compare groups for primary and secondary outcomes
12b Methods for additional analyses, such as subgroup analyses and adjusted analyses
Results
Participant flow (a diagram is strongly recommended) 13a For each group, the numbers of participants who were randomly assigned received 
intended treatment and were analyzed for the primary outcome
13b For each group, losses and exclusions after randomization, together with reasons
Recruitment 14a Dates defining the periods of recruitment and follow-up
14b Why the trial ended or was stopped
Baseline data 15 A table showing the baseline demographic and clinical characteristics for each group
Numbers analyzed 16 For each group, number of participants (denominator) included in each analysis and 
whether the analysis was by original assigned groups
Outcomes and estimation 17a For each primary and secondary outcome, results for each group, and the estimated 
effect size and its precision (such as 95% confidence interval)
17b For binary outcomes, presentation of both absolute and relative effect sizes is recommended
Ancillary analyses 18 Results of any other analyses performed, including subgroup analyses and adjusted 
analyses, distinguishing pre-specified from exploratory
Harms 19 All important harms or unintended effects in each group (for specific guidance see 
CONSORT for harms)
Discussion
Limitations 20 Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, the 
multiplicity of analyses
Generalizability 21 Generalizability (external validity, applicability) of the trial findings
Interpretation 22 Interpretation consistent with results, balancing benefits and harms, and considering 
other relevant evidence
Other information
Registration 23 Registration number and name of trial registry
Protocol 24 Where the full trial protocol can be accessed, if available
Funding 25 Sources of funding and other support (such as the supply of drugs), the role of funders
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manuscript as describing a trial. Furthermore, correct 
indexing also enhances the visibility of a researcher’s 
work and increases the citation potential of the published 
manuscript. Citation of published manuscripts is imperative 
for the enhancement of the researcher’s research metrics 
and for increasing the prestigious acknowledgment of the 
researcher and his/her work within the scientific community.[5]
The abstract should include a structured, brief, and clear 
summary of the study while presenting information found 
within the actual body of the manuscript. The abstract needs 
to be well written, since readers tend to assess the overall 
quality of the trial just by reading the abstract. Furthermore, 
since not all trial reports are fully freely available for readers, 
the abstract may be the only source of initial information 
accessible to readers.[3]
Item 2: Introduction
The Introduction section sets the scientific scene and 
rational as to why the trial was essential. Trials involving 
human subjects should have an ethical clearance and exhibit 
substantial benefit toward mankind.
The objective and hypothesis set out to be investigated in 
the trial should be reported clearly in this section.
Item 3 to 12: Methods
The Methods section should include a detailed report of how 
the trial was conducted including the type of design followed 
and the description of the protocol followed. The type of trial 
conducted needs to be noted clearly i.e., whether it consisted 
of a parallel group design or a factorial design.[3] The most 
common trial design followed is a randomized parallel group 
design, and in fact the CONSORT statement focuses mainly 
on such a trial design.[6] It is essential that all the eligibility 
criteria utilized in the trial protocol are clearly defined since 
this will enable the reader to interpret the study results 
adequately. Furthermore, the setting and location (county, 
city, hospital, and clinic) of the trial needs to be reported, 
since such information impacts on the study’s validity.[3]
Sufficient detail on the intervention and the control groups 
are required to enable the reproducibility of the trial. When 
a drug intervention trial is being reported, it is essential that 
the drug name, dose, mode of administration, timing, and 
duration details are provided.
The outcome measures, be it primary or secondary outcome, 
should be identified and defined as part of the Methods 
section in order to allow readers to use the same outcomes 
for their own setting.[7] It is not uncommon that the initial 
Figure 1: The CONSORT 2010 flowchart
Enrollment Assessed for eligibility (n =  )
Excluded (n =   )
•   Not meeting inclusion criteria (n =  )
•   Declined to participate (n =  )
•   Other reasons (n =  )
Randomized (n =  )
Allocated to intervention (n =  )
• Received allocated intervention (n =  )
• Did not receive allocated intervention
  (give reasons) (n =  )
Allocated to intervention (n =  )
• Received allocated intervention (n =  )
• Did not receive allocated intervention
  (give reasons) (n =  )
Lost to follow-up (give reasons) (n =  )
Discontinued intervention (give reasons)
(n =  )
Lost to follow-up (give reasons) (n =  )
Discontinued intervention (give
reasons) (n =  )
Analyzed (n =  )
• Excluded from analysis (give reasons)
  (n =  )
Analyzed (n =  )
• Excluded from analysis (give
  reasons) (n =  )
Allocation
Follow-Up
Analysis
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objective and protocol are amended throughout the course 
of the trial. In which case, this change should be reported.
The process of establishing an ethically and scientifically 
approved trial sample size needs to be noted and justified. 
Such information needs to provide evidence of the statistical 
power of the sample population under study. Furthermore, 
the randomization protocol of the sample population into 
the intervention and the control groups must be noted. Trials 
that follow a blinding protocol need to ensure the following: 
how such blinding was done, who knew about the blinding, 
was blinding initiated from the start of the trial, among other 
details. This is to ensure that any potential bias in the results 
is identified and accounted for.[3]
A detailed description of all the statistical analyses of the data 
obtained from all stages of the trial needs to be reported.
Item 13 to 19: Results
The CONSORT flowchart, as seen in Figure 1, is provided to 
guide the author to the details required in the Results section. 
It is strongly recommended that the author utilizes the 
CONSORT flowchart to illustrate the trial outcomes. A detailed 
account of the intervention and the control groups are required 
including any loss of follow‑up and any individual exclusion 
that occurred during the trial. If the trial ended prematurely, 
the reasons contributing to this need to be reported. It is 
suggestible to illustrate the baseline characteristics of the 
population under study followed by the primary and secondary 
outcomes of the study. Furthermore, any harms or unintended 
effects originating from the trial need to be reported.
Item 20 to 22: Discussion
The Discussion section should include supporting evidence 
to the trial’s findings along with the pros and cons of the 
results obtained. Any external validation performed needs 
to be reported and discussed.
Item 23: Other information
The clinical trial should be registered at the very beginning 
in order to avoid any patency or infringement issues. 
Such details are required to be included in the manuscript 
reporting the clinical trial. The details of where a reader can 
access the full trial protocol needs to be included as well. 
Clinical trials are very expensive to conduct and funding will 
be required for it to be successful. All funding sources and 
the role of the funders in the trial’s protocol are imperative 
to be stated in manuscripts.
Conclusion
The CONSORT statement is a constantly updated guideline 
developed to aid RCTs authors in adequately reporting any 
trial. A 25‑checklist and a flowchart comprise the CONSORT 
statement. Reporting and publishing trials in any journal 
require the authors to follow the CONSORT statement while 
writing their manuscript to ensure publication consideration.
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